Arcus Biosciences Appoints Global Immuno-Oncology Commercial Leader, Eric Hoefer as Chief Commercial Officer
24 Junho 2019 - 5:10PM
Business Wire
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage
biopharmaceutical company focused on creating innovative cancer
therapies, today announced that Eric Hoefer has joined the Company
as Chief Commercial Officer. Mr. Hoefer will oversee all aspects of
the Company’s global commercial strategy and operations as the
Company works to ensure that it most efficiently leverages the
clinical and market development opportunities for its therapeutic
candidates.
“Eric has extensive knowledge of the global clinical and
commercial oncology treatment landscape. He will bring significant
content expertise and leadership as Arcus advances its product
candidates through clinical studies to potentially expand access
broadly to all patients who may benefit from these therapies,” said
Terry Rosen, Ph.D., Chief Executive Officer of Arcus. “His insights
into identifying underserved patient populations and settings,
market development opportunities and potential approaches to
accelerate development programs will be invaluable as the company
evolves towards later-stage clinical studies.”
“I am honored to join this highly regarded team of experts in
both oncology and immunology,” commented Mr. Hoefer. “I look
forward to building the capabilities to potentially accelerate how
we’ll bring new options to patients with significant unmet medical
needs.”
During the span of Mr. Hoefer’s 20-year career in biopharma, he
has been instrumental to the development and commercialization of
15 new medicines, including Avastin®, Tarceva®,
Tecentriq®, and Imfinzi®. His diverse experience
spans global product strategy, global marketing, product
development, and U.S. marketing and sales leadership. Mr. Hoefer
was most recently at AstraZeneca, where he led Immuno-Oncology (IO)
Global Marketing and launched Imfinzi as the first immuno-oncology
medicine approved in the curative-intent lung cancer setting. Prior
to joining AstraZeneca, Mr. Hoefer launched seven new medicines
during an approximately 14-year tenure with Roche/Genentech. From
2015-2017, Mr. Hoefer co-led the creation of Roche’s Phase 1b/2 IO
platform (MORPHEUS) to adaptively assess and accelerate novel
combination approvals across seven tumor types. Also, during his
tenure, Mr. Hoefer led the commercial development for late-stage GI
oncology assets. Mr. Hoefer began his biopharma career in primary
care and specialty care sales for GlaxoWellcome. In 2002, as a
Congressional Health Policy Analyst for the Chairman of the House
Ways & Means Committee, he was involved in developing the
Medicare Modernization Act, including Part B reform and the Part D
prescription drug benefit.
Mr. Hoefer received Master’s degrees in Business Administration
and Public Policy from Duke University. In addition, Mr. Hoefer
holds Bachelor of Science degrees in Molecular Biology and
Economics from Duke University.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company
focused on creating innovative cancer therapies. Arcus has several
programs targeting important oncology/immuno-oncology pathways,
including a dual adenosine receptor antagonist, AB928, which is in
a Phase 1/1b program to evaluate AB928 in combination with other
agents in multiple tumor types, and an anti-PD-1 antibody, AB122,
which is being evaluated in a Phase 1 trial and is being tested in
combination with Arcus’s other product candidates. Arcus’s other
programs include AB154, an anti-TIGIT antibody, which is being
evaluated in a Phase 1 trial as monotherapy and in combination with
AB122, and AB680, a small-molecule inhibitor of CD73, which is in a
Phase 1 healthy volunteer study. Arcus has extensive in-house
expertise in medicinal chemistry, oncology, immunology,
biochemistry, pharmacology and structural biology. Utilizing these
unique capabilities, Arcus has developed a robust and active
early-stage discovery effort focused on small-molecule pipeline
expansion. For more information about Arcus Biosciences, please
visit www.arcusbio.com.
Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including, but not limited to, the potential of our product
candidates, clinical and market development opportunities, and
potential to accelerate our development programs, are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
All forward-looking statements involve known and unknown risks,
uncertainties and other important factors that may cause Arcus’s
actual results, performance or achievements to differ significantly
from those expressed or implied. Factors that could cause or
contribute to such differences include, but are not limited to, the
inherent uncertainty associated with pharmaceutical product
development and clinical trials, the emergence of adverse events or
other undesirable side effects, delays in our clinical trials due
to difficulties or delays in the regulatory process, enrolling
subjects or manufacturing or supplying product for such clinical
trials, disagreements with regulatory authorities regarding our
clinical development plans and changes in the competitive landscape
for our programs. Risks and uncertainties facing Arcus are
described more fully in Arcus’s most recent Annual Report on Form
10-K and Quarterly Report on Form 10-Q filed with the U.S.
Securities and Exchange Commission. You are cautioned not to place
undue reliance on the forward-looking statements, which speak only
as of the date of this press release. Arcus disclaims any
obligation or undertaking to update, supplement or revise any
forward-looking statements contained in this press release.
The Arcus name and logo are trademarks of Arcus. All other
trademarks belong to their respective owners.
Source: Arcus Biosciences
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190624005462/en/
Katherine Bock (415) 533-5670 kbock@arcusbio.com Nicole Arndt
(510) 284-4728 narndt@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024